It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Platelets contract forcefully after their activation, contributing to the strength and stability of platelet aggregates and fibrin clots during blood coagulation. Viscoelastic approaches can be used to assess platelet-induced clot strengthening, but they require thrombin and fibrin generation and are unable to measure platelet forces directly. Here, we report a rapid, microfluidic approach for measuring the contractile force of platelet aggregates for the detection of platelet dysfunction. We find that platelet forces are significantly reduced when blood samples are treated with inhibitors of myosin, GPIb-IX-V, integrin αIIbβ3, P2Y12, or thromboxane generation. Clinically, we find that platelet forces are measurably lower in cardiology patients taking aspirin. We also find that measuring platelet forces can identify Emergency Department trauma patients who subsequently require blood transfusions. Together, these findings indicate that microfluidic quantification of platelet forces may be a rapid and useful approach for monitoring both antiplatelet therapy and traumatic bleeding risk.
Platelet aggregates generate contractile forces that contribute to their cohesion and adhesion. Here, Ting et al. develop a microfluidic device to measure contractile forces generated by platelet aggregates, and find it can detect the response of platelets to pharmacological agents and predict bleeding risk in trauma patients.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 University of Washington, Mechanical Engineering, Seattle, USA (GRID:grid.34477.33) (ISNI:0000000122986657)
2 University of Washington, Department of Emergency Medicine, Seattle, USA (GRID:grid.34477.33) (ISNI:0000000122986657)
3 University of Washington, Biostatistics, Seattle, USA (GRID:grid.34477.33) (ISNI:0000000122986657)
4 University of Washington, Mechanical Engineering, Seattle, USA (GRID:grid.34477.33) (ISNI:0000000122986657); University of Washington, Department of Emergency Medicine, Seattle, USA (GRID:grid.34477.33) (ISNI:0000000122986657); University of Washington, Bioengineering, Seattle, USA (GRID:grid.34477.33) (ISNI:0000000122986657)
5 University of Washington, Mechanical Engineering, Seattle, USA (GRID:grid.34477.33) (ISNI:0000000122986657); University of Washington, Bioengineering, Seattle, USA (GRID:grid.34477.33) (ISNI:0000000122986657); University of Washington, Institute for Stem Cell and Regenerative Medicine, Seattle, USA (GRID:grid.34477.33) (ISNI:0000000122986657)